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OBJECTIVE— Islet transplantation alone is an alternative for the replacement of pancreatic
endocrine function in patients with type 1 diabetes. The aim of our study was to assess the impact of
the Edmonton immunosuppressive protocol (tacrolimus-sirolimus association) on kidney function.
RESEARCH DESIGN ANDMETHODS— Nineteen patients with type 1 diabetes and
metabolic instability received islet transplantation alone and immunosuppressive therapy ac-
cording to the Edmonton protocol. Serum creatinine (sCr), creatinine clearance (CrCl), and 24-h
urinary protein excretion (UPE) were assessed at baseline and during a follow-up of 339 patient-
months.
RESULTS— After islet transplantation we observed 1) sCr within the normal range in all but
two patients in whom sCr increased immediately after islet transplantation, and despite with-
drawal of immunosuppression, patients progressed to end-stage renal disease (ESRD); 2) CrCl
remained within the normal range for those patients who had normal baseline values and
decreased, progressing to ESRD in two patients with a decreased baseline CrCl; and 3) 24-h UPE
worsened (300 mg/24 h) in four patients. In the two patients who progressed to ESRD, the
worsening of 24-h UPE occurred immediately after islet transplantation. In one patient 24-h UPE
worsening occurred at 18 months, and, after withdrawal of immunosuppression, it returned to
the normal range. In another patient 24-h UPE increased at 24 months and remained stable while
immunosuppression was continued.
CONCLUSIONS— In type 1 diabetic patients receiving islet transplantation alone, the
association of tacrolimus and sirolimus should be used only in patients with normal kidney
function. Alternative options for immunosuppressive treatment should be considered for pa-
tients with even a mild decrease of kidney function.
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The Diabetes Control and Complica-tions Trial has shown that in pa-tients with type 1 diabetes, intensive
diabetes treatment reduces incidence and
delays progression of long-term compli-
cations (1). The Epidemiology of Diabetes
Intervention and Complications (EDIC)
study, a follow-up of the original Diabetes
Control and Complications Trial cohort,
has shown a sustained effect of intensive
diabetes treatment on the development
and progression of nephropathy and ma-
crovascular disease (2). Furthermore, the
EDIC study has shown that patients with
type 1 diabetes with some endogenous C-
peptide reserve have a lower risk of pro-
gression of retinopathy and neuropathy
(2). However, the benefits of intensive di-
abetes treatment come with the price of
severe hypoglycemia and increased body
weight (1).
Several studies have reported a high
rate of insulin independence and normal-
ization of blood glucose and A1C levels
after either pancreas or islet transplanta-
tion (3–7). In patients with type 1 diabe-
tes, pancreas or islet transplantation has
improved kidney graft survival (8,9),
whereas the positive impact of pancreas
transplantation on the native kidney has
been counterbalanced by the nephrotox-
icity of immunosuppressants, namely cal-
cineurin inhibitors (10,11).
Since the advent of the Edmonton
protocol, islet transplantation alone, i.e.,
regardless of the need for kidney trans-
plantation, has been proposed for pa-
tients with type 1 diabetes who have an
increased risk of acute or chronic compli-
cations (3). However, few data have been
reported on kidney function after islet
transplantation alone (12,13), despite im-
munosuppression according to the Edm-
onton protocol, which is the association
of two potentially nephrotoxic drugs,
namely tacrolimus and sirolimus (14 –
16). The aim of our study was to assess the
impact of the Edmonton immunosup-
pressive protocol on kidney function after
islet transplantation alone in patients with
type 1 diabetes.
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RESEARCH DESIGN AND
METHODS— For the purpose of this
study, we analyzed data on 19 patients
who received islet transplantation at the
San Raffaele Scientific Institute between
February 2001 and March 2005. Patients
with type 1 diabetes were eligible for islet
transplantation alone if they met the fol-
lowing criteria: 1) diabetes duration 5
years, 2) decreased awareness of hypogly-
cemia, 3) metabolic instability, or 4) pro-
gressive chronic complications despite an
intensive insulin regimen (i.e.,4 insulin
injections/day or continuous subcutane-
ous insulin infusion). Patients with severe
cardiovascular disease, evidence of pro-
gressive nephropathy (urinary protein
excretion 500 mg/24 h or serum creat-
inine 135 mol/l), a history of chronic
infectious disease (viral hepatitis or tuber-
culosis), or malignancy were not eligible.
Patients were 10 men and 9 women,
with mean  SD age of 37.2  9.0 years
(range 2–61) and duration of diabetes of
23.3 9.0 years (11–37). All patients had
decreased hypoglycemia awareness, 11
patients had retinopathy, 12 patients
had peripheral neuropathy, and 1 patient
had gastroparesis. Four patients had hy-
pertension and were treated with ACE
inhibitors. Two patients had mild nephrop-
athy: one patient had macroproteinuria
for 2 years before islet transplantation and
the other had a serum creatinine level of
132.60 mol/l, a normal albumin excre-
tion rate, and hypertension. None of the
patients had macroangiopathy.
Immunosuppression
All patients were treated according to the
Edmonton protocol (3). Briefly, the pro-
tocol is 1) daclizumab, 1 mg/kg every 2
weeks for 10 weeks, repeated after each
additional islet infusion; 2) sirolimus, a
loading dose of 0.2 mg/kg, followed by a
maintenance dose of 0.1 mg/kg once
daily, with target plasma levels of 12–15
ng/ml during the first 3 months and then
10–12 ng/ml thereafter; and 3) tacroli-
mus, twice daily, starting at the dose of 2
mg/day adjusted to achieve a target
plasma level of 3–6 ng/ml. In six patients,
sirolimus was withdrawn because of side
effects (mouth ulcers, joint pain, or
edema) after 24 14 weeks and replaced
by mycophenolate mofetil (MMF), 2
g/day. After 12 months of immunosup-
pression with tacrolimus and MMF, one
patient was changed from tacrolimus to
cyclosporine because of tremor.
Other medications
Short-term antibiotic prophylaxis was ad-
ministered immediately before and after
islet infusion (intravenous cephtazidime,
1 g t.i.d. for 1 day). For 3 months after
islet infusion, patients were treated with
trimethoprim (800 mg/day once a day),
sulfamethoxazole (160 mg/day once a
day), and acyclovir (200 mg t.i.d.) to pre-
vent Pneumocystis carinii and cytomegalo-
virus infection. In six patients, acyclovir
was stopped because of gastric intoler-
ance. Fifteen patients were treated with
statins because of hypercholesterolemia
and four patients with ACE inhibitors be-
cause of macroproteinuria (n  1) or hy-
pertension (n 3). During the first 3 days
after islet infusion, insulin was adminis-
tered intravenously using an infusion
pump and then was administered subcu-
taneously until withdrawal.
Islet transplantation
Islets were isolated from pancreata ob-
tained from heart-beating cadaveric mul-
tiorgan donors, using an automated
method, modified as described previ-
ously (17). Purification was performed by
the centrifugation on discontinuous Fi-
coll gradients (Sigma Chemical, St. Louis,
MO) and was assayed by a computerized
morphometric method (Leica Imaging
System LDD, Cambridge, U.K.). Islets
were cultured in M199 medium supple-
mented with 10% FCS, 1% L-glutamine,
100 units/ml penicillin, and 100 g/ml
streptomycin and incubated at 30°C in
5% CO2 and 95% humidified air for
2–48 h. Islets were tested for sterility,
endotoxin (Chromogenic LAL test; Bio-
Whittaker, Walkersville, MD), and Myco-
plasma (Mycoplasma detection kit;
Boehringer Mannheim, Indianapolis, IN).
Islets were infused in the liver according
to the protocol approved by our institu-
tional review board, as reported previ-
ously (18,19). In brief, an ultrasound
imager was used for guidance during por-
tal vein puncture with a 22-gauge needle
under local anesthesia. Portography was
performed before and after islet infusion
to confirm the correct positioning of the
catheter and the patency of the portal
vein. Two patients received one islet infu-
sion, 11 patients received two islet infu-
sions, and 6 patients received three islet
infusions (mean SD islet infusion 2.1
0.7). The value for islet equivalents was
11,477 3,970 islets/kg of body weight.
Follow-up
Nineteen patients had 3 months of fol-
low-up, 18 patients had 6 months, 17 pa-
tients had 12 months, 13 patients had 18
months, and 8 patients had 24 months.
Total follow-up was 339 patient-months;
median follow-up was 18 patient-months
(range 3–24). Two patients dropped out
of the study at 8 and 12 months, respec-
tively, when immunosuppression was
withdrawn because of deterioration of
kidney function. One patient elected to
withdraw from the study at 4 months be-
cause of intolerance to immunosuppres-
sion; in one patient immunosuppression
was withdrawn after 21 months because
of graft failure.
The following variables were mea-
sured at baseline and every 3 months after
the first islet infusion: A1C (percent), fast-
ing C-peptide (nanomoles per liter), ex-
ogenous insulin requirement, episodes of
severe hypoglycemia, serum creatinine
(sCr) (micromoles per liter), creatinine
clearance (CrCl) (milliliters per second)
estimated using the Cockcroft-Gault
equation (20), and 24-h urinary protein
excretion (UPE) (grams per 24 h).
Statistical analysis
Statistical analysis was performed using
SPSS for Windows (version 10.1; SPSS,
Chicago, IL). Data are presented as
means  SD. A two-sided paired Stu-
dent’s t test was used to compare means at
baseline versus follow-up. P  0.05 (by
two-tailed testing) was considered statis-
tically significant.
RESULTS
Islet function
Pretransplant A1C was 8.6  0.03% and
decreased significantly after islet trans-
plantation: 6.6 0.2% at 3 months (P
0.001 vs. pretransplant), 6.2 0.2% at 6
months (P  0.001 vs. pretransplant),
6.8  0.2% at 12 months (P  0.001 vs.
pretransplant), 6.9 0.3% at 18 months
(P 0.001 vs. pretransplant), and 6.4
0.2 at 24 months (P  0.02 vs. pretrans-
plant). Fasting C-peptide was 0.01 
0.01 nmol/l at baseline. Fasting C-peptide
0.17 nmol/l was detected immediately
after the first islet infusion in all patients.
Mean fasting C-peptide values during fol-
low-up were 0.33  0.03 nmol/l at 3
months, 0.40 0.03 nmol/l at 6 months,
0.46 0.07 nmol/l at 12 months, 0.53
0.07 nmol/l at 18 months, and 0.50 
0.03 nmol/l at 24 months (P  0.001 vs.
pretransplant). The need for exogenous
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insulin therapy is reported in Fig. 1. No
episodes of severe hypoglycemia were re-
corded after islet transplantation, even
when patients were receiving exogenous
insulin therapy.
Kidney function
All patients. sCr, CrCl, and 24-h UPE
values for individual patients are shown
in Fig. 2. sCr levels at baseline were all in
the normal range, except for one patient
who had a sCr of 133 mol/l. sCr re-
mained within the normal range for the
entire follow-up in all but two patients in
whom sCr increased immediately after is-
let transplantation. Despite immunosup-
pression withdrawal, patients progressed
to end-stage renal disease (ESRD).
Similarly, all CrCl pretransplant val-
ues were within the normal range, except
for two patients who had CrCl values of
0.76 and 0.72 ml/s, respectively. After is-
let transplantation, CrCl remained within
the normal range throughout the entire
follow-up for those patients who had nor-
mal baseline CrCl and decreased, pro-
gressing to ESRD in the two patients with
a decreased baseline CrCl.
After islet transplantation, 24-h UPE
worsened (300 mg/24 h) in four pa-
tients. In the two patients who progressed
to ESRD, the worsening of 24-h UPE oc-
curred immediately after islet transplan-
tation. In one patient, 24-h UPE
worsened at 18 months; after withdrawal
of immunosuppression because of islet
transplant failure, 24-h UPE returned to
the normal range. In another patient,
24-h UPE increased at 24 months and re-
mained stable, despite continued immu-
nosuppression (data at 36 months, not
shown).
After an average of 4.5 1.3 months
from the first islet infusion, sirolimus was
withdrawn in six patients because of sig-
nificant side effects (mouth ulcers, joint
pain, and edema), and treatment with
MMF was then started. CrCl and 24-h
UPE for these six patients are shown in
Fig. 3. After the shift from sirolimus to
MMF, CrCl decreased in one patient from
1.6 ml/s at baseline to 0.8 ml/s at month 6
and remained stable thereafter (patient
11), whereas 24-h UPE increased in an-
other patient from 18 mg/24 h at baseline
to 240 mg/24 h at 24 months (patient 8).
Patients with nephropathy before islet
transplantation. Two patients had mild
nephropathy before islet transplantation.
Patient 4 had microalbuminuria for 2
years before islet transplantation and was
treated with ACE inhibitors. At baseline
sCr was 88mol/l and 24-h UPE was 195
mg/24 h. The patient received two infu-
sions of islets and became insulin inde-
pendent 4 weeks after the second
infusion. A1C decreased from 11.6 to
6.2% in 3 months. After 1 month 24-h
UPE increased to 3,300 mg/24 h, without
changes in sCr (85.75 mol/l). At 6
months, an increase in sCr (288 mol/l)
and a further increase in 24-h UPE (4,600
mg/24 h) were observed. Immunosup-
pression was reduced, and tacrolimus was
stopped. Nevertheless, kidney function
continued to deteriorate. Sirolimus was
withdrawn at 9 months; however, there
was no improvement in kidney function.
The patient started hemodialysis and was
put on a list for a combined kidney-
pancreas transplant. Patient 6 developed
hypertension 1 year before islet trans-
plantation and was treated with ACE in-
hibitors. The patient received a single
infusion of islets and became insulin in-
dependent after 3 weeks. A1C decreased
from 7.5 to 6.1% at 6 months. Baseline
sCr was 133 mol/l and 24-h UPE was
133 mg/24 h. sCr increased to 188mol/l
at 1 month and to 235 mol/l at 3
months. Proteinuria was detected for the
first time at 3 months (3,330 mg/24 h).
Because of the deterioration of kidney
function, tacrolimus was withdrawn, but
no improvement in kidney function was
observed. At 7 months, sCr reached 277
mol/l and sirolimus also was stopped,
with no further increase in sCr. One year
after immunosuppressive treatment was
completely withdrawn, sCr was 327.08
mol/l and 24-h UPE was 1,000 mg/24 h.
CONCLUSIONS— Our study shows
that baseline kidney function among pa-
tients with type 1 diabetes receiving islet
transplantation alone predicts deteriora-
tion of kidney function during immuno-
suppression according to the Edmonton
protocol. In fact, during our follow-up of
339 patient-months after islet transplan-
tation, deterioration of kidney function
occurred in two patients whose baseline
kidney function was mildly decreased
and in none of the patients whose baseline
kidney function was normal.
Many studies have demonstrated the
effect of restoring endocrine pancreatic
function, i.e., pancreas or islet transplan-
tation, on the development and progres-
sion of diabetic nephropathy. Kidney
biopsy studies by Fioretto et al. (10,11)
demonstrated that pancreas transplanta-
tion can reverse the glomerular changes of
diabetic nephropathy and that the rever-
sal was evident 10 years after pancreas
transplantation but not after 5 years when
Figure 1—Insulin therapy in 19 patients with type 1 diabetes who received islet transplantation
alone and the Edmonton protocol (3). The vertical line across the bars indicates additional islet
transplantations.
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only functional and morphological signs
of cyclosporine nephrotoxicity were evi-
dent. However, immunosuppression
consisted of only one potentially nephro-
toxic drug (i.e., cyclosporine), and insulin
independence was prolonged for a de-
cade. In patients who underwent simulta-
neous pancreas-kidney or islet-kidney
transplantation, improved cumulative
survival, kidney graft size, and function
were reported in the group with a func-
tioning pancreas or islets (9). Further-
more, insulin independence was not
required for a positive effect on kidney
function (8), supporting the EDIC finding
that patients with type 1 diabetes with re-
sidual C-peptide function have a lower
risk of diabetic nephropathy (2). The
question of how to balance the risks and
benefits of islet transplantation in regard
to kidney function is still unanswered.
In the Edmonton protocol, immuno-
suppression after islet transplantation
alone in patients with type 1 diabetes is
based on the association of tacrolimus
and sirolimus (3). Tacrolimus nephrotox-
icity is well described, whereas the effects
of sirolimus on kidney function are just
emerging (14). In kidney transplant re-
cipients, sirolimus was not nephrotoxic,
unless combined with calcineurin inhibi-
tors (15). However, the association of ta-
crolimus and sirolimus increased delayed
graft function rate by threefold in kidney
transplant recipients (15) and caused
acute graft failure in living donor kidney
recipients (21). Furthermore, sirolimus
can be nephrotoxic to the native kidney as
reported in patients with chronic glo-
merulopathies (22). Sirolimus nephro-
toxicity is due to direct tubular damage
and, to a lesser degree, to glomerular
damage. In fact, sirolimus inhibits growth
factor–induced proliferation of cultured
proximal tubular cells and induces apo-
ptosis (23). This effect is mediated by the
inhibition of a 70-kDa S6 protein kinase
needed for cell cycle progression (24).
The early and progressive deterioration of
kidney function that occurred in two of
our patients who progressed to ESRD af-
ter islet transplantation may be explained
by increased nephrotoxicity with tacroli-
mus and sirolimus in individuals with
some degree of glomerular damage due to
diabetic nephropathy and tubular dam-
age due to the use of these immunosup-
pressive drugs. Furthermore, the extent of
glomerular damage in patients with type 1
diabetes may somehow be masked by the
widespread use of ACE inhibitors, as in-
deed may have been the case in one of our
patients (25).
Similarly, tacrolimus-sirolimus neph-
rotoxicity, rather than progression of dia-
betic nephropathy, may have caused the
progressive increase in UPE that we ob-
served in two patients who did not have
any sign of diabetic nephropathy before
islet transplantation. In fact, withdrawal
of immunosuppression in one of them re-
sulted in the decrease of proteinuria,
whereas in the other patient proteinuria
remained stable for up to 36 months (data
not shown), despite immunosuppression.
Impairment of renal function was re-
ported in a few patients receiving islet
transplants after kidney transplant who
were switched from their former immu-
nosuppressive regimen to a low-dose ta-
crolimus and sirolimus combination (12).
Recently Senior et al. (13) reported three
cases of proteinuria in islet transplant re-
cipients treated with the association of ta-
crolimus and sirolimus. Proteinuria
resolved after sirolimus was replaced with
MMF and treatment with ACE inhibitors
and angiotensin-2 receptor blockers was
started. In these patients, the reduction of
proteinuria was associated with a reduc-
tion of CrCl, and both findings may be
related to progression of diabetic ne-
phropathy observed within 6 months.
Our observations on progression of
diabetic nephropathy in patients who un-
derwent islet transplantation alone have
Figure 2—sCr (micromol per liter) (upper panel), CrCl (milliliters per second) (middle panel),
and 24-h UPE (milligrams per 24 h) (lower panel) in 19 patients with type 1 diabetes who
received islet transplantation alone and immunosuppression according to the Edmonton protocol
(3). Patients in sirolimus was replaced by MMF are reported until sirolimus withdrawal. Pre tx,
pretreatment.
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to be considered in the risk-benefit rate
evaluation before the procedure. In pa-
tients who have had diabetes for many
years and are showing the initial signs of
microangiopathy, as microalbuminuria,
or who have been treated with ACE inhib-
itors, the association of tacrolimus and
sirolimus should be avoided because it
can trigger the irreversible progression of
diabetic nephropathy, which was not
counterbalanced in any patient by an im-
provement in metabolic control.
In summary, in type 1 diabetic patients
receiving islet transplantation alone, the as-
sociation of tacrolimus and sirolimus
should be used only in patients with normal
kidney function. Alternative options for im-
munosuppressive treatment should be con-
sidered for patients with even a mild
decrease in kidney function.
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